Caprock Group LLC Has $279,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Caprock Group LLC boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 16.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 792 shares of the biotechnology company’s stock after buying an additional 111 shares during the period. Caprock Group LLC’s holdings in United Therapeutics were worth $279,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. USA Financial Formulas bought a new position in shares of United Therapeutics during the 3rd quarter worth approximately $33,000. Brooklyn Investment Group acquired a new position in United Therapeutics during the third quarter worth $33,000. Capital Performance Advisors LLP bought a new position in United Therapeutics in the third quarter valued at $82,000. MassMutual Private Wealth & Trust FSB increased its stake in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in United Therapeutics during the 3rd quarter worth about $90,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $353.75 on Friday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The company has a market capitalization of $15.79 billion, a price-to-earnings ratio of 15.54, a PEG ratio of 0.92 and a beta of 0.57. The company has a 50-day simple moving average of $363.31 and a 200 day simple moving average of $357.63.

Analysts Set New Price Targets

UTHR has been the subject of several analyst reports. UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. LADENBURG THALM/SH SH boosted their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Oppenheimer increased their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $382.08.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of United Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 128,614 shares of company stock worth $47,868,005 over the last three months. Insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.